The FDA has approved SIMTRIYO, a new daily extended-release tablet containing centanafadine, as a treatment option for attention deficit hyperactivity disorder (ADHD) in adults and children ages 6 and older who weigh at least 44 pounds. Developed by Otsuka Pharmaceutical, SIMTRIYO is being described as the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) approved for ADHD, introducing a treatment that targets three key neurotransmitters simultaneously.
Regulatory status and timing
SIMTRIYO’s approval by the FDA clears the way for it to reach the U.S. market, with the company expecting it to be available by prescription later this year. The drug will still undergo hearings with the Drug Enforcement Administration (DEA) to determine its final scheduling classification.
Clinical trial evidence
Otsuka based its application on data from four phase 3 trials that enrolled adults, adolescents, and children with ADHD. Company reports indicate that participants taking centanafadine showed statistically significant and clinically meaningful reductions in ADHD symptoms compared with placebo. Two trials in adults tested 200 mg and 400 mg doses; separate large studies included 459 adolescents (ages 13–17) and 480 children (ages 6–12). A recent phase 3b study also found benefit in adults with ADHD and coexisting anxiety symptoms.
Safety and side effects
Common adverse events seen across the trials included:
– In children and adolescents: decreased appetite, nausea, rash, headache, abdominal pain.
– In adults: headache, decreased appetite, insomnia, nausea, dry mouth, diarrhea.
SIMTRIYO carries a boxed warning for risk of suicidal ideation and behaviors in pediatric patients, as well as a boxed warning about the potential for abuse, misuse, and addiction. Clinicians will need to weigh these risks when considering treatment and monitor patients closely, particularly younger patients.
How clinicians view the new option
Child and adult ADHD specialists contacted about the approval say the drug adds a useful alternative to existing therapies. Some expect to reserve SIMTRIYO as a second-line or backup option for patients who don’t respond adequately to current stimulant or nonstimulant medications, at least initially. Others note that because SIMTRIYO acts on three neurotransmitters rather than one or two, it may help patients who have had limited benefit from other drugs. Wider use will depend on real-world experience and more head-to-head comparisons with established stimulant treatments.
ADHD overview and treatment context
ADHD is a common neurodevelopmental condition that can impair attention, impulse control, and activity level, affecting school, work, relationships, and daily functioning. The CDC estimates roughly 7 million U.S. children (ages 3–17) and about 15 million adults carry an ADHD diagnosis; many adults are diagnosed later in life.
Symptoms can include difficulty sustaining focus, forgetfulness, distractibility, restlessness, and interrupting others. ADHD is commonly categorized as predominantly inattentive, predominantly hyperactive-impulsive, or combined presentation. Causes are not fully understood but involve neurological differences and genetic factors.
Treatment is individualized and often combines behavioral therapies with medication. Behavioral interventions, organization and study supports, sleep hygiene, exercise, and family or school accommodations are important components of care—medication can reduce core symptoms and help patients engage in therapy and daily tasks more effectively. Common medication classes include stimulant drugs (e.g., methylphenidate and amphetamine formulations) and nonstimulants (e.g., atomoxetine); SIMTRIYO will join these options as an oral daily treatment with a distinct mechanism.
Practical considerations
Clinicians say families and patients should not ignore ADHD and that treatment plans should be tailored to the individual. For children, parental involvement with schools—such as arranging quiet homework spaces, additional test time, or classroom supports—can be critical. When SIMTRIYO becomes available, prescribers will evaluate each patient’s history, response to prior medications, coexisting conditions (including anxiety or mood disorders), and risk factors for misuse before choosing a regimen.
Bottom line
SIMTRIYO represents a new pharmacologic approach for ADHD by targeting norepinephrine, dopamine, and serotonin reuptake. Early trials demonstrate symptomatic improvement across age groups, but the drug comes with important safety warnings, especially for pediatric patients. It is likely to be adopted initially as an alternative for patients who have not responded to existing treatments, with broader use to follow as postmarketing experience accumulates. Availability by prescription is expected later this year pending DEA scheduling decisions.